Resting Full-cycle Ratio-guided Step by Step Balloon Dilation

NCT ID: NCT05107024

Last Updated: 2021-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-01

Study Completion Date

2023-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Drug-coated balloon (DCB), as an implant-free treatment technique, has been widely used in coronary interventional therapy, effectively solving the problem of restenosis caused by traditional stent implantation, and providing a treatment option for patients with coronary heart disease with high blood risk. However, in DCB treatment of coronary artery lesions, the incidence of dissection is as high as 10-20% when the balloon is predilated, which often requires salvage stent implantation, resulting in the treatment failure of DCB and bringing great hidden dangers to patients. The main reason was that excessive balloon predilation was caused by the standard of vascular anatomy (residual lumen stenosis less than 30%). The resting full cycle ratio (RFR) is a reliable method for determining the presence of functional ischemia in coronary artery lesions and enables immediate detection. We hypothesized that RFR-guided stepped-balloon dilation could reduce the incidence of dissection and increase the success rate of DCB treatment. Fifty patients who planned to receive DCB treatment were randomly divided into balloon dilation alone (n=25) and RFR-guided stepped-balloon dilation group (n=25). The primary endpoint was the success rate of DCB treatment. This study will provide a functional evaluation based balloon predilation method for DCB treatment, making DCB treatment for orthotopic coronary artery disease more safe and effective.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To compare the application of pre-treated lesions with DCB in the treatment of coronary artery disease in situ between the simple balloon dilation group and rFR-guided stepped-balloon dilation group.

It was a single-center, open, prospective, randomized controlled study. Fifty patients with symptoms of myocardial ischemia or relevant evidence for DCB treatment of coronary artery disease in situ were enrolled and randomly divided into balloon dilation group alone (n=25) and rFR-guided step balloon dilation group (n=25).

In the balloon dilation group, the optimal size of the semi-compliant balloon was determined by the surgeon according to angiography (the ratio of balloon to blood vessel was 1.0), and full predilation was performed to achieve residual stenosis. 30% vascular anatomy criteria, and then a 1:1 DCB was selected for drug release; The step balloon expansion group guided by RFR expanded from 2.0mm compliant balloon. After 8atm pressure expansion, the RFR value was measured. If RFR≥0.93, the pre-expansion was stopped. 0.93, RFR value is measured after pressure expansion of 16atm, if RFR\&lt is still; 0.93, then a 2.5mm compliant or non-compliant balloon was used to expand the pressure of 8ATM, and the balloon diameter and expansion pressure were continuously increased until RFR≥0.93, and then A DCB with the same diameter as the pre-expanded balloon was selected for drug release. If c-type or higher dissection or TIMI flow occurs \& LT; Grade 3 patients were given salvage stents.

Collect patient history and improve clinical examination; The occurrence and classification of dissection, final pre-dilated balloon diameter, DCB diameter, incidence of salvage stent implantation, residual stenosis, operation time, and radiation dose were recorded intraoperatively. The incidence of revascularization and angina pectoris during hospitalization were recorded. Minimum lumen diameter and diameter stenosis rate were detected by coronary angiography 9 months after discharge. MACE events were observed 12 months after discharge.

With residual lumens stenosis less than 30% as the criteria the pure balloon pre expansion of coronary artery lesions in situ can result in up to 10-40% of the incidence of retrospective stenting, limits the DCB in coronary artery lesions in situ treatment, the application of quasi simple balloon expansion and pathological changes of RFR guiding ladder balloon expansion of pretreatment in the DCB treatment of coronary artery lesions, the application of in situ To verify that rFR-guided stepped-balloon dilation compared with balloon dilation alone can increase the success rate of DCB in the treatment of orthotopic coronary artery lesions, thus providing a new pre-dilation treatment method for DCB to be more effective and safe in the application of orthotopic coronary artery lesions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

de Novo Coronary Lesions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Traditional balloon dilation group

The optimal size of the semi-compliant balloon (balloon to vessel ratio 1.0) was determined by the surgeon according to angiography, and sufficient predilation was performed to achieve residual stenosis. 30% vascular anatomy criteria, and then a 1:1 DCB was selected for drug release

Group Type ACTIVE_COMPARATOR

Traditional balloon dilation

Intervention Type DEVICE

The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria

RFR-guided step by step balloon dilation group

Balloon dilation start with 2.0mm compliant balloon. After 8atm pressure expansion, the RFR value was measured. If RFR≥0.93, the pre-expansion was stopped. Otherwise, RFR value is measured after pressure expansion of 16atm, if RFR value is still less than 0.93, then a 2.5mm compliant or non-compliant balloon was used to expand the pressure of 8ATM, and the balloon diameter and expansion pressure were continuously increased until RFR≥0.93. Then a DCB with the same diameter as the pre-expanded balloon was selected for drug release.

Group Type EXPERIMENTAL

RFR-guided step by step balloon dilation

Intervention Type DEVICE

The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RFR-guided step by step balloon dilation

The mean value of the minimum ratio of distal mean pressure to aortic mean pressure (Pd/Pa) in five consecutive complete cardiac cycles was obtained by scanning the diastolic and systolic stages at rest.

Intervention Type DEVICE

Traditional balloon dilation

The surgeon determines the optimal size of the semi-compliant balloon based on angiography (balloon to vessel ratio 1.0) and performs adequate predilation to achieve residual stenosis. 30% of vascular anatomy criteria

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years old; Presenting with stable or unstable angina and/or evidence of myocardial ischemia; The treated lesions were in situ coronary artery lesions. Angiography showed lumen diameter of 2.5-4.0mm and diameter stenosis ≥80%. No more than 2 lesions require treatment.

Exclusion Criteria

* Acute myocardial infarction within 48 hours of onset; Life expectancy of less than 12 months; Lesion in left main trunk, lesion length \> 24mm, severe calcification, thrombosis or bifurcation; There are other lesions that require stenting.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shenzhen People's Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shaohong Dong

Role: STUDY_CHAIR

Shenzhen People's Hospital

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xin Sun

Role: CONTACT

Phone: +86-755-22943205

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Shenzhen REDUCE

Identifier Type: -

Identifier Source: org_study_id